Investor Relations

Latest Financial Results

Q2 2018

Quarter Ended Jun 30, 2018

Latest 10-K

View Latest 10-K

Stock Information


Nasdaq: HTBX




52 week Low/High

Day Low/High

Company Overview

Heat Biologics a biopharmaceutical company that develops immunotherapies to activate a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

View Our Corporate Presentation


Heat Biologics, Inc.
801 Capitola Drive
Suite 12
Durham, NC 27713
+1 919 240 7133

Investor Relations

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
+1 212 509 4000